The Canadian Multicentre CSF Monitoring and Biomarker Study



Status:Recruiting
Conditions:Hospital, Orthopedic
Therapuetic Areas:Orthopedics / Podiatry, Other
Healthy:No
Age Range:17 - Any
Updated:10/28/2017
Start Date:January 2011
End Date:March 2019
Contact:Allison Coleman, BSc, CCRP
Email:acoleman@rickhanseninstitute.org
Phone:604-827-1852

Use our guide to learn which trials are right for you!

The purpose of this study is to:

1. Measure the pressure in the spinal fluid surrounding the spinal cord to find out how
well the spinal cord is being supplied with blood.

2. Determine how drugs called "vasopressors", which are used to control blood pressure
following SCI (spinal cord injury), influence spinal fluid pressure.

3. Characterize the severity of an SCI using the levels of specific proteins found within
the spinal fluid.

4. Predict how much neurologic recovery may be regained using the levels of specific
proteins within your spinal fluid.

5. Identify proteins within the spinal fluid that will help us learn more about what is
happening after SCI and assist us in developing new treatments for SCI.

This research project consists of two complementary yet distinct initiatives:

1. First, we will prospectively evaluate spinal cord perfusion pressure(SCPP)in patients
with acute spinal cord injuries, to provide scientifically-based guidelines on the
management of blood pressure during the acute injury phase.

2. Second, we will evaluate cerebrospinal fluid(CSF) samples from these patients with the
goal of prospectively validating a series of biochemical markers that correlate with
injury severity and predict neurologic outcome. Ultimately, our goals are to enhance the
neurologic outcome of individuals with spinal cord injuries by improving upon their
acute clinical care, and to establish biological surrogates of injury severity that may
be used to facilitate clinical trials of novel therapeutic interventions for acute
spinal cord injury.

Specific Aims

This multicenter study will enroll patients with acute traumatic cervical and thoracic SCI
within 48 hours of their injury. A lumbar intrathecal catheter will be inserted
pre-operatively for the measurement of intrathecal pressure (ITP) and the collection of CSF
samples. Spinal cord perfusion pressure will be calculated as the difference between mean
arterial pressure (MAP) and the ITP. The objectives of this aspect of the study will be to:

- Document the changes in SCPP over the first 5-7 days post-injury (with an intrathecal
catheter that is in place for 5 days).

- Determine the effect of different vasopressor agents on SCPP.

Additionally, CSF samples will be obtained from the intrathecal catheter at 8-hour intervals
to analyse the expression of the following biochemical markers: including interleukin (IL)-6,
IL-8, monocyte chemo-attractant protein (MCP)-1, glial fibrillary acidic protein (GFAP),
S100beta, and tau. The objectives of this aspect of the study will be to:

- Evaluate the accuracy of these inflammatory and neuronal markers at classifying the
initial severity of paralysis and at predicting the extent of neurologic recovery.

- Characterize the temporal pattern of expression of these proteins to provide a more
complete description of the human pathophysiology of SCI.

Inclusion Criteria:

- 17 years of age or older

- Complete (AIS A)or incomplete (AIS B, C) acute SCI involving bony spinal levels
between C0 and L1

- Non-penetrating injury

- Able to communicate in English and provide informed consent

- Enrolled within 48 hours after injury and able to provide CSF and blood samples within
this period

Exclusion Criteria:

- SCI that involves sensory impairment only (i.e., no impairment in ability to move arms
and legs)

- Penetrating spinal cord injury

- Isolated radiculopathy (injury only to the nerve outside of the spinal cord)

- Cauda equina injury (injury to nerve roots at the end of the spinal cord)

- Severe injury to head at the time of the SCI

- Injury to lower back (below the spinal level L1)

- Major injury to legs, arms, pelvis, chest, or abdomen that make it impossible for
doctors to tell how severely injured the spinal cord is

- Have a pre-existing neurological disorder such as Parkinson's disease, Alzheimer's
disease, Huntington's disease, or multiple sclerosis or amyotrophic lateral sclerosis.

- Pre-existing thromboembolic disease or coagulopathy (disorders related to blood
clotting), such as haemophilia or von Willebrand's disease

- Pre-existing and ongoing infection in the body (e.g., pneumonia, urinary tract
infection, cellulitis)

- Pre-existing inflammatory or autoimmune disorder such as rheumatoid arthritis,
systemic lupus, psoriasis

- Systemic disease that may interfere with safety or evaluation of the condition we're
studying (e.g., heart disease, HIV, HTLV-1)

- Any other medical condition that in the investigator's opinion would render the study
procedures dangerous or impair ability to receive study therapy

- Pregnancy
We found this trial at
3
sites
Vancouver, British Columbia
Principal Investigator: Brian K. Kwon, MD,PhD,FRCSC
?
mi
from
Vancouver,
Click here to add this to my saved trials
San Francisco, California 94110
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
?
mi
from
Stanford, CA
Click here to add this to my saved trials